Sr. Director, Medical Affairs - EU

Liquidia•,

2d•Remote

About The Position

The Senior Director, Medical Affairs EU is a strategic field-based medical leader responsible for advancing Liquidia’s scientific and medical objectives across Europe in pulmonary hypertension and related cardiopulmonary diseases. This role will lead regional scientific engagement, support evidence-generation initiatives, cultivate strategic relationships with key opinion leaders (KOLs), investigators, and patient advocacy organizations, and partner cross-functionally to support the successful execution of clinical development and future commercialization activities throughout Europe. The successful candidate will possess deep therapeutic expertise in PAH and PH-ILD, strong clinical research and external engagement experience, and a demonstrated ability to influence scientific strategy within a complex matrix environment. This individual will serve as a critical scientific ambassador for Liquidia across the European pulmonary vascular community.

Requirements

Advanced scientific degree (PharmD, PhD, MD) required.
More than 15 years of Medical Affairs experience in biotech or pharmaceutical industries, including significant field-based experience as an MSL.
Strong therapeutic expertise in PAH, PH-ILD, pulmonary hypertension, interstitial lung disease, or related cardiopulmonary conditions preferred.
Deep understanding of clinical research processes, including best practices and support models for investigator-initiated research (IIR).
Excellent communication, interpersonal, and coaching skills with a demonstrated ability to motivate and develop field personnel.
Highly organized, with strong analytical ability and comfort working in a fast-paced, cross-functional environment.
Ability to travel 60% across Europe.

Nice To Haves

Strong therapeutic expertise in PAH, PH-ILD, pulmonary hypertension, interstitial lung disease, or related cardiopulmonary conditions.

Responsibilities

Lead development and execution of the European Medical Affairs strategy aligned with global objectives and regional unmet medical needs in PAH and PH-ILD.
Establish Liquidia as a scientific leader within the European pulmonary vascular community through high-impact scientific exchange and strategic external engagement.
Develop regional and national KOL engagement plans targeting pulmonary hypertension centers of excellence, multidisciplinary care teams, investigators, and scientific societies.
Support EU launch readiness activities, including L606 scientific platform development, stakeholder mapping, advisory engagement, and medical education initiatives.
Maintain and develop materials related to advanced knowledge of emerging science, treatment paradigms, competitive intelligence, and evolving clinical practice within pulmonary vascular disease.
Build and maintain strong scientific relationships with KOLs, investigators, site networks, and patient advocacy groups across Europe.
Represent Medical Affairs at international, national, and regional scientific congresses and ensure coordinated scientific engagement and effective post-congress follow-up activities.
Identify opportunities to influence scientific dialogue, evidence-generation priorities, and treatment paradigms in PAH and PH-ILD.
Support scientific exchange related to clinical development programs, unmet medical needs, and real-world treatment challenges.